|
1
|
Evans JM, Donnelly LA, Emslie-Smith AM, et
al: Metformin and reduced risk of cancer in diabetic patients. BMJ.
330:1304–1305. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Decensi A, Puntoni M, Goodwin P, et al:
Metformin and cancer risk in diabetic patients: a systematic review
and meta-analysis. Cancer Prev Res (Phila). 3:1451–1461. 2010.
View Article : Google Scholar
|
|
3
|
Noto H, Goto A, Tsujimoto T and Noda M:
Cancer risk in diabetic patients treated with metformin: a
systematic review and meta-analysis. PLoS One. 7:e334112012.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Martin-Castillo B, Vazquez-Martin A,
Oliveras-Ferraros C and Menendez JA: Metformin and cancer: doses,
mechanisms and the dandelion and hormetic phenomena. Cell Cycle.
9:1057–1064. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Quinn BJ, Kitagawa H, Memmott RM, et al:
Repositioning metformin for cancer prevention and treatment. Trends
Endocrinol Metab. 24:469–480. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hanna RK, Zhou C, Malloy KM, et al:
Metformin potentiates the effects of paclitaxel in endometrial
cancer cells through inhibition of cell proliferation and
modulation of the mTOR pathway. Gynecol Oncol. 125:458–469. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dong L, Zhou Q, Zhang Z, et al: Metformin
sensitizes endometrial cancer cells to chemotherapy by repressing
glyoxalase I expression. J Obstet Gynaecol Res. 38:1077–1085. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shank JJ, Yang K, Ghannam J, et al:
Metformin targets ovarian cancer stem cells in vitro and in vivo.
Gynecol Oncol. 127:390–397. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu H, Scholz C, Zang C, et al: Metformin
and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer
cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
Anticancer Res. 32:1627–1637. 2012.PubMed/NCBI
|
|
10
|
Ashinuma H, Takiguchi Y, Kitazono S, et
al: Antiproliferative action of metformin in human lung cancer cell
lines. Oncol Rep. 28:8–14. 2012.PubMed/NCBI
|
|
11
|
Rattan R, Graham RP, Maguire JL, et al:
Metformin suppresses ovarian cancer growth and metastasis with
enhancement of cisplatin cytotoxicity in vivo. Neoplasia.
13:483–491. 2011.PubMed/NCBI
|
|
12
|
Kim HG, Hien TT, Han EH, et al: Metformin
inhibits P-glycoprotein expression via the NF-κB pathway and CRE
transcriptional activity through AMPK activation. Br J Pharmacol.
162:1096–1108. 2011. View Article : Google Scholar :
|
|
13
|
Rocha GZ, Dias MM, Ropelle ER, et al:
Metformin amplifies chemotherapy-induced AMPK activation and
antitumoral growth. Clin Cancer Res. 17:3993–4005. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nilsson S, Huelsenbeck J and Fritz G:
Mevalonate pathway inhibitors affect anticancer drug-induced cell
death and DNA damage response of human sarcoma cells. Cancer Lett.
304:60–69. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Iliopoulos D, Hirsch HA and Struhl K:
Metformin decreases the dose of chemotherapy for prolonging tumor
remission in mouse xenografts involving multiple cancer cell types.
Cancer Res. 71:3196–3201. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Janjetovic K, Vucicevic L, Misirkic M, et
al: Metformin reduces cisplatin-mediated apoptotic death of cancer
cells through AMPK-independent activation of Akt. Eur J Pharmacol.
651:41–50. 2011. View Article : Google Scholar
|
|
17
|
Yasmeen A, Beauchamp MC, Piura E, et al:
Induction of apoptosis by metformin in epithelial ovarian cancer:
involvement of the Bcl-2 family proteins. Gynecol Oncol.
121:492–498. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Harhaji-Trajkovic L, Vilimanovich U,
Kravic-Stevovic T, et al: AMPK-mediated autophagy inhibits
apoptosis in cisplatintreated tumour cells. J Cell Mol Med.
13:3644–3654. 2009. View Article : Google Scholar
|
|
19
|
Hirsch HA, Iliopoulos D, Tsichlis PN and
Struhl K: Metformin selectively targets cancer stem cells, and acts
together with chemotherapy to block tumor growth and prolong
remission. Cancer Res. 69:7507–7511. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gotlieb WH, Saumet J, Beauchamp MC, et al:
In vitro metformin anti-neoplastic activity in epithelial ovarian
cancer. Gynecol Oncol. 110:246–250. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Graham GG, Punt J, Arora M, et al:
Clinical pharmacokinetics of metformin. Clin Pharmacokinet.
50:81–98. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lalau JD, Lacroix C, Compagnon P, et al:
Role of metformin accumulation in metformin-associated lactic
acidosis. Diabetes Care. 18:779–784. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Martin MJ, Hayward R, Viros A and Marais
R: Metformin accelerates the growth of BRAF V600E-driven melanoma
by upregulating VEGF-A. Cancer Discov. 2:344–355. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Berridge MV, Herst PM and Tan AS:
Tetrazolium dyes as tools in cell biology: new insights into their
cellular reduction. Biotechnol Annu Rev. 11:127–152. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ishiyama M, Miyazono Y, Sasamoto K, et al:
A highly water-soluble disulfonated tetrazolium salt as a
chromogenic indicator for NADH as well as cell viability. Talanta.
44:1299–1305. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Collier AC and Pritsos CA: The
mitochondrial uncoupler dicumarol disrupts the MTT assay. Biochem
Pharmacol. 66:281–287. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pagliacci MC, Spinozzi F, Migliorati G, et
al: Genistein inhibits tumour cell growth in vitro but enhances
mitochondrial reduction of tetrazolium salts: a further pitfall in
the use of the MTT assay for evaluating cell growth and survival.
Eur J Cancer. 29A:1573–1577. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Burzawa JK, Schmeler KM, Soliman PT, et
al: Prospective evaluation of insulin resistance among endometrial
cancer patients. Am J Obstet Gynecol. 204:355.e1–7. 2011.
View Article : Google Scholar
|
|
29
|
Soliman PT, Wu D, Tortolero-Luna G, et al:
Association between adiponectin, insulin resistance, and
endometrial cancer. Cancer. 106:2376–2381. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mu N, Zhu Y, Wang Y, et al: Insulin
resistance: a significant risk factor of endometrial cancer.
Gynecol Oncol. 125:751–757. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Johnson N, Bryant A, Miles T, et al:
Adjuvant chemotherapy for endometrial cancer after hysterectomy.
Cochrane Database Syst Rev. 10:CD0031752011.PubMed/NCBI
|
|
32
|
Vale CL, Tierney J, Bull SJ and Symonds
PR: Chemotherapy for advanced, recurrent or metastatic endometrial
carcinoma. Cochrane Database Syst Rev. 8:CD0039152012.PubMed/NCBI
|
|
33
|
El-Mir MY, Nogueira V, Fontaine E, et al:
Dimethylbiguanide inhibits cell respiration via an indirect effect
targeted on the respiratory chain complex I. J Biol Chem.
275:223–228. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Owen MR, Doran E and Halestrap AP:
Evidence that metformin exerts its anti-diabetic effects through
inhibition of complex 1 of the mitochondrial respiratory chain.
Biochem J. 348:607–614. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wilcock C and Bailey CJ: Accumulation of
metformin by tissues of the normal and diabetic mouse. Xenobiotica.
24:49–57. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cantrell LF, Nelson CL, Gary RD and
McIntyre IM: Fatal metformin intoxication with markedly elevated
blood and liver concentrations. J Anal Toxicol. 36:657–659. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sanchez-Alvarez R, Martinez-Outschoorn UE,
Lamb R, et al: Mitochondrial dysfunction in breast cancer cells
prevents tumor growth: understanding chemoprevention with
metformin. Cell Cycle. 12:172–182. 2013. View Article : Google Scholar :
|
|
38
|
Poot M, Zhang YZ, Krämer JA, et al:
Analysis of mitochondrial morphology and function with novel
fixable fluorescent stains. J Histochem Cytochem. 44:1363–1372.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Renehan AG, Tyson M, Egger M, et al:
Body-mass index and incidence of cancer: a systematic review and
meta-analysis of prospective observational studies. Lancet.
371:569–578. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Jiralerspong S, Palla SL, Giordano SH, et
al: Metformin and pathologic complete responses to neoadjuvant
chemotherapy in diabetic patients with breast cancer. J Clin Oncol.
27:3297–3302. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Goodwin PJ, Pritchard KI, Ennis M, et al:
Insulin-lowering effects of metformin in women with early breast
cancer. Clin Breast Cancer. 8:501–505. 2008. View Article : Google Scholar : PubMed/NCBI
|
